BioNTech stock last at EUR 87.05, down 0.46 percent in Xetra trading
Published on 09/25/2026 at 20:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
BioNTech stock was last at EUR 87.05 on Xetra at 11:31 a.m. CET on September 25, 2026, down 0.46 percent. The US ADS was down 0.32 percent at 2:18 p.m. ET, while the Nasdaq Composite gained 151.36 points. The US-listed ADS was trading at USD 98.94 with the session still running.
The session on September 25, 2026 in figures
BioNTech SE (ISIN US09075V1026) was last at EUR 87.05 on Xetra at 11:31 a.m. CET, according to the quoted market panel. The Xetra trading range extended from EUR 86.60 to EUR 87.45, putting the latest level EUR 0.40 below the session high. The US ADS opened at USD 99.53 and traded between USD 97.72 and USD 100.02 by 2:18 p.m. ET.
The US ADS volume stood at 348,931 shares at 2:18 p.m. ET, against a prior-session reference of USD 99.26. The latest US level was USD 0.32 below that reference, while the Nasdaq Composite was 151.36 points higher. BioNTech's US session therefore lagged the technology-heavy index on the available percentage measure.
Analyst support and market pressure
Finanzen reported on September 16, 2026, that Berenberg analyst Harry Gillis retained a Buy rating and raised the target from USD 132 to USD 140. Berenberg cited strong lung cancer study results involving pumitamig and elfetabart. The report said investors reacted only slightly to the research note.
MarketBeat reported on September 25, 2026, that BioNTech CEO Ugur Sahin sold 30,000 shares. Reuters reported that higher oil prices and elevated euro zone bond yields pressured European risk appetite on September 24, 2026. Reuters also said European technology shares fell 1.6 percent and the STOXX 600 fell 0.6 percent.
Biotech peers and US trading on September 25, 2026
Moderna traded at USD 197.66 at 2:19 p.m. ET, up 1.46 percent, with volume of 9.85 million shares. Gilead Sciences stood at USD 149.81, up 0.08 percent, at 2:19 p.m. ET. Regeneron traded at USD 791.08, down 0.62 percent, while its session range ran from USD 784.13 to USD 803.87.
The Nasdaq Composite stood at 27,090.73 at 2:19 p.m. ET, up 151.36 points. BioNTech's USD 98.94 level was USD 1.28 below Moderna's quoted price. The biotechnology group therefore showed mixed intraday performance, with Moderna higher, Gilead nearly unchanged and Regeneron lower.
